Unknown

Dataset Information

0

Nicotiana benthamiana ?-galactosidase A1.1 can functionally complement human ?-galactosidase A deficiency associated with Fabry disease.


ABSTRACT: ?-Galactosidases (EC 3.2.1.22) are retaining glycosidases that cleave terminal ?-linked galactose residues from glycoconjugate substrates. ?-Galactosidases take part in the turnover of cell wall-associated galactomannans in plants and in the lysosomal degradation of glycosphingolipids in animals. Deficiency of human ?-galactosidase A (?-Gal A) causes Fabry disease (FD), a heritable, X-linked lysosomal storage disorder, characterized by accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3). Current management of FD involves enzyme-replacement therapy (ERT). An activity-based probe (ABP) covalently labeling the catalytic nucleophile of ?-Gal A has been previously designed to study ?-galactosidases for use in FD therapy. Here, we report that this ABP labels proteins in Nicotiana benthamiana leaf extracts, enabling the identification and biochemical characterization of an N. benthamiana ?-galactosidase we name here A1.1 (gene accession ID GJZM-1660). The transiently overexpressed and purified enzyme was a monomer lacking N-glycans and was active toward 4-methylumbelliferyl-?-d-galactopyranoside substrate (Km = 0.17 mm) over a broad pH range. A1.1 structural analysis by X-ray crystallography revealed marked similarities with human ?-Gal A, even including A1.1's ability to hydrolyze Gb3 and lyso-Gb3, which are not endogenous in plants. Of note, A1.1 uptake into FD fibroblasts reduced the elevated lyso-Gb3 levels in these cells, consistent with A1.1 delivery to lysosomes as revealed by confocal microscopy. The ease of production and the features of A1.1, such as stability over a broad pH range, combined with its capacity to degrade glycosphingolipid substrates, warrant further examination of its value as a potential therapeutic agent for ERT-based FD management.

SUBMITTER: Kytidou K 

PROVIDER: S-EPMC6028973 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

<i>Nicotiana benthamiana</i> α-galactosidase A1.1 can functionally complement human α-galactosidase A deficiency associated with Fabry disease.

Kytidou Kassiani K   Beekwilder Jules J   Artola Marta M   van Meel Eline E   Wilbers Ruud H P RHP   Moolenaar Geri F GF   Goosen Nora N   Ferraz Maria J MJ   Katzy Rebecca R   Voskamp Patrick P   Florea Bogdan I BI   Hokke Cornelis H CH   Overkleeft Herman S HS   Schots Arjen A   Bosch Dirk D   Pannu Navraj N   Aerts Johannes M F G JMFG  

The Journal of biological chemistry 20180419 26


α-Galactosidases (EC 3.2.1.22) are retaining glycosidases that cleave terminal α-linked galactose residues from glycoconjugate substrates. α-Galactosidases take part in the turnover of cell wall-associated galactomannans in plants and in the lysosomal degradation of glycosphingolipids in animals. Deficiency of human α-galactosidase A (α-Gal A) causes Fabry disease (FD), a heritable, X-linked lysosomal storage disorder, characterized by accumulation of globotriaosylceramide (Gb3) and globotriaosy  ...[more]

Similar Datasets

| S-EPMC3340376 | biostudies-literature
| S-EPMC4855861 | biostudies-literature
| S-EPMC8583658 | biostudies-literature
| S-EPMC6396734 | biostudies-literature
| S-EPMC5478728 | biostudies-literature
| S-EPMC6599056 | biostudies-literature
| S-EPMC6320285 | biostudies-literature
| S-EPMC3176300 | biostudies-literature
| S-EPMC8234732 | biostudies-literature
| S-EPMC6629127 | biostudies-literature